Legal status · United States
Is Neuropeptide Y legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Neuropeptide Y is not an approved medicine in the United States; its classification is "Not a medicine; endogenous signalling molecule". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Neuropeptide Y in the United States at a glance
| Classification | Not a medicine; endogenous signalling molecule |
|---|---|
| Note | NPY is a neuropeptide your own brain and sympathetic nerves make. Unlike most entries in this class, there is no approved medicine acting at its receptors to point to: the largest attempt, the Y5 antagonist MK-0557, completed a 52 week randomised trial in 1,661 patients and was abandoned because the weight loss was not clinically meaningful. |
| FDA approval status | NPY is an endogenous neuropeptide, not a drug, and there is no approved product containing it. No drug acting at any NPY receptor is approved for obesity or for any other indication. Intranasal NPY has been studied in a phase 1 trial in PTSD. |
| Human studies cited | 3 of 5 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Neuropeptide Y profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Neuropeptide Y is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Neuropeptide Y is
The most potent appetite-driving peptide known when injected into a rodent brain. The one large human test of the idea, a 52 week trial of a Y5 receptor blocker in 1,661 overweight and obese adults, produced weight loss its own authors called not clinically meaningful. The only trial of NPY itself in people gave it intranasally to 26 patients with PTSD.
Neuropeptide Y is one of the most abundant neuropeptides in the mammalian brain and a co-transmitter released alongside noradrenaline from sympathetic nerves. It is a 36 amino acid peptide and it belongs to one structural family with peptide YY and pancreatic polypeptide, which is why the three are almost always discussed together.
Mechanism: NPY signals through a family of class A G protein-coupled receptors. In humans, Y1, Y2, Y4 and Y5 are functional.
Regulatory history: NPY is an endogenous neuropeptide, not a drug, and there is no approved product containing it. No drug acting at any NPY receptor is approved for obesity or for any other indication. Intranasal NPY has been studied in a phase 1 trial in PTSD.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Neuropeptide Y at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Neuropeptide Y in other countries
United Kingdom
Not approvedNot a medicine; endogenous signalling molecule
Is Neuropeptide Y legal in the United Kingdom?Australia
Not approvedNot a medicine; endogenous signalling molecule
Is Neuropeptide Y legal in Australia?Canada
Not approvedNot a medicine; endogenous signalling molecule
Is Neuropeptide Y legal in Canada?Frequently asked questions
Is Neuropeptide Y legal in the United States?
No. Neuropeptide Y is not an approved medicine in the United States; its classification is "Not a medicine; endogenous signalling molecule". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: NPY is a neuropeptide your own brain and sympathetic nerves make. Unlike most entries in this class, there is no approved medicine acting at its receptors to point to: the largest attempt, the Y5 antagonist MK-0557, completed a 52 week randomised trial in 1,661 patients and was abandoned because the weight loss was not clinically meaningful.
Can I buy Neuropeptide Y in the United States?
No approved product exists to buy. In the United States Neuropeptide Y is classified as "Not a medicine; endogenous signalling molecule", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: NPY is a neuropeptide your own brain and sympathetic nerves make. Unlike most entries in this class, there is no approved medicine acting at its receptors to point to: the largest attempt, the Y5 antagonist MK-0557, completed a 52 week randomised trial in 1,661 patients and was abandoned because the weight loss was not clinically meaningful.
Is Neuropeptide Y FDA approved?
No. FDA status: NPY is an endogenous neuropeptide, not a drug, and there is no approved product containing it. No drug acting at any NPY receptor is approved for obesity or for any other indication. Intranasal NPY has been studied in a phase 1 trial in PTSD.. Current US classification: "Not a medicine; endogenous signalling molecule". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Neuropeptide Y live on its compound profile.
Neuropeptide Y profileThis page is general information about the regulatory status of Neuropeptide Y in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.